KRAS Inhibitors: Targeting the 'Undruggable' Mutation in 2026 and Beyond

Once deemed "undruggable" due to its smooth surface and high affinity for GTP, the KRAS oncogene has become a prime target in precision oncology. KRAS mutations drive approximately 20-30% of all cancers, with high prevalence in non-small cell lung cancer (NSCLC, ~30%), colorectal cancer (CRC, ~40%), and pancreatic ductal adenocarcinoma (PDAC, >90%). The most common mutation historically was G12C, but breakthroughs now extend to G12D, G12V, and multi-selective "pan-KRAS" approaches.

Update: KRAS Inhibitors: Targeting the 'Undruggable' Mutation in 2026 and Beyond

Key Breakthroughs in KRAS G12C Inhibitors

The pioneering covalent inhibitors sotorasib (Lumakras) and adagrasib (Krazati), approved earlier for KRAS G12C-mutated NSCLC, saw major expansions in 2025:

• January 2025 FDA approval: Sotorasib combined with panitumumab (Vectibix, an EGFR inhibitor) for previously treated KRAS G12C-mutated metastatic CRC. This combination addresses adaptive resistance via EGFR feedback, achieving higher objective response rates (ORR ~26%) and progression-free survival (PFS ~5.6 months) compared to monotherapy.

Next-generation G12C inhibitors like olomorasib and divarasib show promise in overcoming resistance, with ongoing trials exploring first-line combinations with immunotherapy.Advances Beyond G12C: Targeting G12D and Multi-Selective InhibitorsG12D dominates in PDAC (~50% of KRAS mutations) and is common in CRC, historically lacking targeted options. 2025 marked exciting progress:

• Daraxonrasib (RMC-6236): A RAS(ON) multi-selective inhibitor targeting active GTP-bound RAS (G12X, G13X, Q61X). In phase 1 trials for previously treated KRAS G12X-mutated metastatic PDAC, it achieved median PFS of 8.8 months and deep tumor regressions. The FDA granted Breakthrough Therapy Designation in mid-2025, highlighting its potential in this deadly cancer.
• VS-7375 (GFH375): An oral KRAS G12D (ON/OFF) selective inhibitor received Fast Track Designation for advanced PDAC (first- or second-line). Early phase 1/2 data showed promising safety and preliminary efficacy.

Other candidates like HRS-4642 and zoldonrasib (G12D-selective) are advancing, with preclinical models demonstrating tumor regression in PDAC and CRC.Pan-KRAS and Pan-RAS StrategiesTo address multiple mutations simultaneously:

• Inhibitors like JAB-23E73 and BBO-11818 entered early clinical trials in 2025, showing broad activity against G12D/V and others in preclinical models.
• Revolution Medicines' pipeline (including elironrasib for G12C) emphasizes tri-complex mechanisms for enhanced potency.

These approaches aim to overcome mutation heterogeneity and resistance.Challenges: Resistance MechanismsDespite advances, resistance limits durability:

• Acquired: Secondary KRAS mutations (e.g., Y96D), pathway reactivation (MAPK/PI3K), MET/EGFR amplification.
• Adaptive/Intrinsic: Bypass signaling, epithelial-to-mesenchymal transition, or aberrant KRAS localization (e.g., cytoplasmic in HER2-amplified tumors).
• Combinations (e.g., with EGFR, SHP2, or MEK inhibitors) and next-gen agents targeting RAS(ON) states are key strategies to delay resistance.

Future Outlook2025 has been a pivotal year, with the first approvals beyond NSCLC and breakthrough designations signaling hope for PDAC patients. Ongoing trials focus on combinations, earlier-line use, and pan-KRAS inhibitors to achieve deeper, longer-lasting responses. Biomarker testing for KRAS mutations is now essential, paving the way for personalized therapies against this once-elusive target.

These developments substantiate a shift: KRAS is no longer undruggable, offering new hope for millions affected by KRAS-driven cancers.

Related:

Noel Watson. Why Has KRAS Been So Difficult to Target in Cancer (Especially Pancreatic Cancer)? Facebook 2026.